Influence of the α α1а-adrenoreceptor blocker on the mechanisms of limination of small stones from the middle third of the ureter

E. Barinov, Kh. V. Grigoryan, Y. Malinin
{"title":"Influence of the α α1а-adrenoreceptor blocker on the mechanisms of limination of small stones from the middle third of the ureter","authors":"E. Barinov, Kh. V. Grigoryan, Y. Malinin","doi":"10.36485/1561-6274-2023-27-1-61-68","DOIUrl":null,"url":null,"abstract":"   BACKGROUND. To date, the mechanisms of small stone elimination by lithokinetic therapy (LCT) have not been elucidated.   THE AIM of this investigation was to estimate the activity of receptors controlling the contraction and relaxation of smooth muscle cells (SMC) against the background of α1A-adrenoreceptor blockade during LCT in patients with small stones localization in the middle third of ureter.   PATIENTS AND METHODS. The study was prospective and included 40 patients in whom standard LCT was done for localization of small concrements (≤6 mm) in the middle third of ureter. The functional activity of receptors modulating ureteric peristalsis was analyzed in vitro using platelet suspension. The agonists used were ATP, ADP, adenosine, epinephrine, angiotensin-2 (Sigma-Aldrich Chemie GmbH, Germany) at EC50 concentrations causing aggregation at 50 % in healthy subjects. Platelet aggregation was assessed by turbidimetric method on ChronoLog analyzer (USA).   RESULTS. No differences in the rate of small concrements elimination from the middle third of ureter was found in presence and absence of α1A-adrenoreceptor blocker in LCT. Before LCT, α2-adrenoreceptor hyperresponsiveness, normoreponsiveness of purine P2X1- and P2Y-receptors, adenosine A2-receptor and angiotensin AT1-receptor were found. After 9 days of LCT with verified elimination of concrements, an increase in P2X1-receptor and AT1-receptor activity (p < 0.001) was found regardless of the administration of α1A-adrenoceptor blocker. P2Y-receptor hyperresponsiveness was seen in the presence and normoreponsiveness in the absence of α1A-adrenoreceptor blocker in LCT.   CONCLUSION. At the lithokinetic therapy irrespective of α1A-adrenoreceptor blocker prescription, compensatory mechanisms, aimed at enhancement of contractile activity and preservation of smooth muscle cell relaxation take part in the traffics of small concrements from the middle third of ureter.","PeriodicalId":19089,"journal":{"name":"Nephrology (Saint-Petersburg)","volume":"232 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology (Saint-Petersburg)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36485/1561-6274-2023-27-1-61-68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

   BACKGROUND. To date, the mechanisms of small stone elimination by lithokinetic therapy (LCT) have not been elucidated.   THE AIM of this investigation was to estimate the activity of receptors controlling the contraction and relaxation of smooth muscle cells (SMC) against the background of α1A-adrenoreceptor blockade during LCT in patients with small stones localization in the middle third of ureter.   PATIENTS AND METHODS. The study was prospective and included 40 patients in whom standard LCT was done for localization of small concrements (≤6 mm) in the middle third of ureter. The functional activity of receptors modulating ureteric peristalsis was analyzed in vitro using platelet suspension. The agonists used were ATP, ADP, adenosine, epinephrine, angiotensin-2 (Sigma-Aldrich Chemie GmbH, Germany) at EC50 concentrations causing aggregation at 50 % in healthy subjects. Platelet aggregation was assessed by turbidimetric method on ChronoLog analyzer (USA).   RESULTS. No differences in the rate of small concrements elimination from the middle third of ureter was found in presence and absence of α1A-adrenoreceptor blocker in LCT. Before LCT, α2-adrenoreceptor hyperresponsiveness, normoreponsiveness of purine P2X1- and P2Y-receptors, adenosine A2-receptor and angiotensin AT1-receptor were found. After 9 days of LCT with verified elimination of concrements, an increase in P2X1-receptor and AT1-receptor activity (p < 0.001) was found regardless of the administration of α1A-adrenoceptor blocker. P2Y-receptor hyperresponsiveness was seen in the presence and normoreponsiveness in the absence of α1A-adrenoreceptor blocker in LCT.   CONCLUSION. At the lithokinetic therapy irrespective of α1A-adrenoreceptor blocker prescription, compensatory mechanisms, aimed at enhancement of contractile activity and preservation of smooth muscle cell relaxation take part in the traffics of small concrements from the middle third of ureter.
α α 11 -肾上腺素受体阻滞剂对输尿管中三分之一小结石清除机制的影响
背景。迄今为止,岩石动力学疗法(LCT)消除小结石的机制尚未阐明。本研究的目的是在α α -肾上腺素受体阻断的背景下,评估输尿管中三分之一小结石患者LCT期间控制平滑肌细胞(SMC)收缩和舒张的受体的活性。患者和方法。该研究是前瞻性的,纳入了40例患者,这些患者采用标准LCT定位输尿管中间三分之一处的小结石(≤6mm)。应用血小板悬浮液分析了受体调节输尿管蠕动的功能活性。使用的激动剂为ATP、ADP、腺苷、肾上腺素、血管紧张素-2 (Sigma-Aldrich Chemie GmbH,德国),浓度为EC50,在健康受试者中引起50%的聚集。血小板聚集用美国ChronoLog分析仪浊度法测定。结果。输尿管中三分之一的小结石清除率在α 1a -肾上腺素受体阻滞剂存在和不存在时无差异。LCT前,大鼠α2-肾上腺素受体高反应性、嘌呤P2X1、p2y受体、腺苷a2受体、血管紧张素at1受体均呈高反应性。LCT治疗9天后,证实了混凝土的消除,无论给予α 1a -肾上腺素受体阻滞剂,p2x1受体和at1受体活性均有所增加(p < 0.001)。LCT中存在p2y受体高反应性,缺乏α 1a -肾上腺素受体阻滞剂时p2y受体低反应性。结论。无论α α -肾上腺素受体阻滞剂处方如何,在碎石运动治疗中,旨在增强收缩活性和保持平滑肌细胞松弛的代偿机制参与了输尿管中部三分之一的小混凝土的运输。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信